Lyso-Globotriaosylceramide, 98%

Name: Lyso-Globotriaosylceramide, 98% | 126550-86-5
Brand: J&K Chemical
SKU: JK320652_1_MG
Price: 2230.27 USD
Availability: OutOfStock

Cat. No JK320652_1_MG

Vendor: J&K Chemical

Product Information

Product Name

Lyso-Globotriaosylceramide, 98%

Brand Name

J&K

Product Number

320652

CAS

126550-86-5

Molecular Formula

C36H67NO17

Molecular Weight

785.91

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

6449939

IUPAC Name

(2R,3R,4S,5R,6R)-2-(2R,3R,4R,5R,6S)-6-(2R,3S,4R,5R,6R)-6-(E,2S,3R)-2-amino-3-hydroxyoctadec-4-enoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yloxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yloxy-6-(hydroxymethyl)oxane-3,4,5-triol

InChI Key

GRGNVOCPFLXGDQ-TWHXEDJUSA-N

SMILES

CCCCCCCCCCCCC/C=C/C@H(C@H(COC@H1C@@H(C@H(C@@H(C@H(O1)CO)OC@H2C@@H(C@H(C@H(C@H(O2)CO)OC@@H3C@@H(C@H(C@H(C@H(O3)CO)O)O)O)O)O)O)O)N)O

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease

Publication Name: Journal of the Formosan Medical Association = Taiwan yi zhi

Publication Date: 2025-09

DOI: 10.1016/j.jfma.2024.09.033

The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review

Publication Name: Molecular Genetics and Metabolism

Publication Date: 2025-06

DOI: 10.1016/j.ymgme.2025.109110

Fabry disease in the haemodialysis population: outcome of a UK screening study (SoFAH)

Publication Name: BMC Nephrology

Publication Date: 2025-05-26

DOI: 10.1186/s12882-025-04127-x

Enhancing Fabry disease screening and diagnostic efficiency: Integration of enzyme, biomarker, and next-generation sequencing testing

Publication Name: Molecular Genetics and Metabolism

Publication Date: 2025-05

DOI: 10.1016/j.ymgme.2025.109082

Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension

Publication Name: Molecular Genetics and Metabolism

Publication Date: 2025-05

DOI: 10.1016/j.ymgme.2025.109102

Lyso-Globotriaosylceramide, 98%

Product Information

General Information

Safety Information

References Data Source From Pubchem

Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease

The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review

Fabry disease in the haemodialysis population: outcome of a UK screening study (SoFAH)

Enhancing Fabry disease screening and diagnostic efficiency: Integration of enzyme, biomarker, and next-generation sequencing testing

Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension